Source-grounded facts extracted from PFIZER INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Cecile Guegan was appointed as Interim Chief Financial Officer at PFIZER INC.
“the Company announced that Cecile Guegan, the Company’s Senior Vice President, Finance, Global Biopharmaceutical Business, will serve as Interim Chief Financial Officer, effective August 16, 2026”
Dave Denton departed as Chief Financial Officer at PFIZER INC.
“Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026”
PFIZER INC reported the first quarter of 2026 results: revenue $14,451, net income 2,687, EPS 0.47. Guidance reaffirmed.
“rates (5) . Results for the first quarter of 2026 and 2025 (6) are summarized below. ($ in millions, except per share amounts) First-Quarter 2026 2025 % Change Revenues $ 14,451 $ 13,715 5% Reported (3) Net Income 2,687 2,967 (9%) Reported (3) Diluted EPS 0.47 0.52 (10%) Adjusted (4) Income 4,290 5,237 (18%) Adjusted (4) Diluted EPS 0.75 0.92 (18%)”
Mortimer J. Buckley was elected as member of the Board at PFIZER INC.
“elected Mortimer J. Buckley to serve as a member of the Company’s Board, effective immediately.”
Mikael Dolsten departed as Chief Scientific Officer and President, Pfizer Research & Development at PFIZER INC.
“On July 9, 2024, Pfizer Inc. (the "Company") announced that it is beginning the process of finding a successor for Dr. Mikael Dolsten, the Company’s Chief Scientific Officer and President, Pfizer Research & Development after his more than 15-year distinguished career with the Company.”
Cyrus Taraporevala was elected as Director at PFIZER INC.
“elected Cyrus Taraporevala to serve as a member of the Company’s Board, effective immediately.”
PFIZER INC announced a restructuring with charges of approximately $1.7 billion affecting cost of goods sold.
“of which is expected to begin being realized in 2025. The one-time costs to achieve the savings associated with the first phase of the program are expected to be approximately $1.7 billion and primarily include severance and implementation costs. These costs will be recorded primarily in 2024, with cash outlays expected in 2025 and 2026. The estimate of costs that”
PFIZER INC reported first quarter of 2024 results: revenue $14,879 million, net income $3,115 million, EPS $0.55. Guidance raised.
“First-Quarter 2024 Results ▪ Solid First-Quarter Results Reflect Continued Growth of Key Products and Progress in Executing 2024 Priorities ▪ First-Quarter 2024 Revenues of $14.9 Billion – Expected Decline in Comirnaty (1) and Paxlovid Revenues Drove a Year-Over-Year Operational Decrease in Revenues of 19% – Excluding Contributions from Comirnaty (1) and”
PFIZER INC shareholders rejected Publish a Report on Corporate Contributions at the 2024-04-25 meeting.
“8. The shareholder proposal to Publish a Report on Corporate Contributions was not approved based upon the following votes: Votes for approval 137,986,751 Votes against 3,505,075,475 Abstentions 59,125,487 Broker non-votes 893,428,132”
PFIZER INC shareholders rejected Publish a Congruency Report on Political, Lobbying, Electioneering Expenditures at the 2024-04-25 meeting.
“6. The shareholder proposal to Publish a Congruency Report on Political, Lobbying, Electioneering Expenditures was not approved based upon the following votes: Votes for approval 515,502,691 Votes against 3,123,669,364 Abstentions 63,015,226 Broker non-votes 893,428,132”
PFIZER INC shareholders rejected Adopt an Independent Board Chair Policy at the 2024-04-25 meeting.
“5. The shareholder proposal to Adopt an Independent Board Chair Policy was not approved based upon the following votes: Votes for approval 1,284,408,190 Votes against 2,391,266,871 Abstentions 26,511,479 Broker non-votes 893,428,132”
PFIZER INC shareholders approved Advisory approval of executive compensation at the 2024-04-25 meeting.
“4. The proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers was approved based upon the following votes: Votes for approval 3,360,637,251 Votes against 315,293,726 Abstentions 26,256,736 Broker non-votes 893,428,132”
PFIZER INC shareholders approved Approval of Amended and Restated Pfizer Inc. 2019 Stock Plan at the 2024-04-25 meeting.
“3. The proposal to approve the Amended and Restated Pfizer Inc. 2019 Stock Plan was approved based upon the following votes : Votes for approval 3,405,629,196 Votes against 275,998,451 Abstentions 20,560,066 Broker non-votes 893,428,132”
PFIZER INC shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for 2024 at the 2024-04-25 meeting.
“2. The proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2024 fiscal year was approved based upon the following votes: Votes for approval 4,315,675,552 Votes against 256,738,678 Abstentions 23,201,615 Broker non-votes n/a”
PFIZER INC shareholders approved Election of Directors at the 2024-04-25 meeting.
“1. The nominees for election to the Company’s Board of Directors set forth in Item 1 to the Company’s Proxy Statement filed with the U.S. Securities and Exchange Commission on March 14, 2024 were elected to hold office until the Company’s next Annual Meeting of Shareholders, based upon the following votes:”
PFIZER INC reported full-year 2024 results: revenue $58.5 to $61.5 Billion, EPS $2.05 to $2.25. Guidance reaffirmed.
“Annual Net Cost Savings by End of 2024 from Previously Announced Cost Realignment Program ▪ Reaffirms Full-Year 2024 Guidance (5) Provided on December 13, 2023, of Revenues of $58.5 to $61.5 Billion and Adjusted (3) Diluted EPS of $2.05 to $2.25 NEW YORK, Tuesday, January 30, 2024 — Pfizer Inc. (NYSE: PFE) reported financial results for fourth quarter and”
PFIZER INC reported fourth-quarter 2023 results: revenue $14.2 Billion, net income ($3,369) million, EPS ($0.60).
“$0.37, Down 93% Year-Over-Year, and Adjusted (3) Diluted EPS of $1.84, Down 72% Year-Over-Year, Significantly Impacted by One-Time Events (4) ▪ Fourth-Quarter 2023 Revenues of $14.2 Billion – Expected Decline in Comirnaty (1) and Paxlovid Revenues Drove 42% Operational Decrease in Fourth-Quarter Revenues – Excluding Contributions from Comirnaty (1) and Paxlovid,”
PFIZER INC reported full-year 2023 results: revenue $58.5 Billion, net income $2,119 million, EPS $0.37.
“Launched Significant Number of New Products and Indications; and Realigned Commercial Organization to Improve Focus, Speed and Execution ▪ Full-Year 2023 Revenues of $58.5 Billion – Expected Decline in Comirnaty (1) and Paxlovid Revenues Drove 41% Operational Decrease in Year-Over-Year Revenues – Excluding Contributions from Comirnaty (1) and Paxlovid,”
PFIZER INC completed an acquisition involving Seagen Inc. for $229 in cash per share, for a total enterprise value of approximately $43 billion (closed 2023-12-14).
“Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.”
PFIZER INC completed an acquisition involving Seagen Inc. for $229.00 in cash per share, for a total enterprise value of approximately $43 billion (closed 2023-12-14).
“Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.”
Angela Hwang resigned as Chief Commercial Officer at PFIZER INC.
“As a result of this reorganization, the role currently held by Angela Hwang, Chief Commercial Officer, Executive Vice President, is being eliminated and she will cease serving in her current role and as a member of the Company’s Executive Leadership Team effective as of December 15, 2023.”
Alexandre de Germay was appointed as Chief International Commercial Officer at PFIZER INC.
“the Pfizer International Commercial Division, which will be led by Alexandre de Germay, who will join Pfizer as Chief International Commercial Officer, Executive Vice President, and will report to Dr. Bourla.”
Aamir Malik was appointed as Chief U.S. Commercial Officer at PFIZER INC.
“the Pfizer U.S. Commercial Division, which will be led by Aamir Malik, who will become Chief U.S. Commercial Officer, Executive Vice President, and continue reporting to Dr. Bourla”
Chris Boshoff was appointed as Chief Oncology Officer at PFIZER INC.
“Pfizer will create an end-to-end business organization called Pfizer Oncology Division, which will integrate certain Oncology Commercial and R&D operations from both Pfizer and Seagen and will be led by Dr. Chris Boshoff, who will become Chief Oncology Officer, Executive Vice President, and continue reporting to Dr. Albert Bourla, Chairman and Chief Executive Officer.”
PFIZER INC reported the third quarter of 2023 results: revenue Revenues of $13.2 Billion, net income Reported (2) Net Income/(Loss) (2,382), EPS Reported (2) Diluted EPS/(LPS) (0.42). Guidance reaffirmed.
“except as shall be expressly set forth by specific reference in such filing. --- EX-99 (EX-99) --- Pfizer Reports Third-Quarter 2023 Results ▪ Third-Quarter 2023 Revenues of $13.2 Billion – Expected Decline in Paxlovid and Comirnaty (1) Revenues Drove 41% Operational Decrease in Third-Quarter 2023 Revenues – Revenues for Pfizer’s Non-COVID Products Grew 10%”
PFIZER INC reported Full-Year 2023 results: EPS $1.45 to $1.65. Guidance lowered.
“Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance”
PFIZER INC announced a restructuring with charges of approximately $3.0 billion affecting enterprise-wide.
“$2.5 billion is expected to be realized in 2024. The one-time costs to achieve the savings associated with the Cost Realignment Program are expected to be approximately $3.0 billion, of which the majority is expected to be cash. These costs will primarily include severance and implementation costs. The estimate of costs that Pfizer expects to incur, and the”
PFIZER INC reported the second quarter of 2023 results: revenue $12,734, net income $2,327, EPS $0.41. Guidance reaffirmed.
“of 2023 and 2022 (5) are summarized below. OVERALL RESULTS ($ in millions, except per share amounts) Second-Quarter Six Months 2023 2022 Change 2023 2022 Change Revenues $ 12,734 $ 27,742 (54%) $ 31,015 $ 53,402 (42%) Reported Net Income (2) 2,327 9,906 (77%) 7,870 17,769 (56%) Reported Diluted EPS (2) 0.41 1.73 (77%) 1.38 3.10 (56%) Adjusted (3) Income”
William Pao departed as Chief Development Officer, Executive Vice President at PFIZER INC.
“As a result of this reorganization, the role held by Dr. William Pao, Chief Development Officer, Executive Vice President, is being eliminated and he will leave the Company effective August 15, 2023.”
Chris Boshoff was appointed as Chief Oncology Research and Development Officer, Executive Vice President at PFIZER INC.
“Effective immediately, Dr. Chris Boshoff, currently Chief Development Officer – Oncology, will become Chief Oncology Research and Development Officer, Executive Vice President”
PFIZER INC reported first quarter of 2023 results: revenue $18,282 million, net income $5,543 million, EPS $0.97 per diluted share. Guidance reaffirmed.
“except as shall be expressly set forth by specific reference in such filing. --- EX-99 (EX-99) --- Pfizer Reports First-Quarter 2023 Results ▪ First-Quarter 2023 Revenues of $18.3 Billion – Expected Decline in Comirnaty (1) Revenue Drove 26% Operational Decrease in First-Quarter 2023 Revenues – First-Quarter 2023 Revenues from Comirnaty (1) and Paxlovid of $7.1”
PFIZER INC shareholders rejected Shareholder proposal regarding political contributions congruency report at the 2023-04-27 meeting.
“The shareholder proposal regarding political contributions congruency report was not approved based upon the following votes:”
PFIZER INC shareholders rejected Shareholder proposal regarding impact of extended patent exclusivities on product access report at the 2023-04-27 meeting.
“The shareholder proposal regarding impact of extended patent exclusivities on product access report was not approved based upon the following votes:”
PFIZER INC shareholders rejected Shareholder proposal regarding transfer of intellectual property to potential COVID-19 manufacturers feasibility report at the 2023-04-27 meeting.
“The shareholder proposal regarding transfer of intellectual property to potential COVID-19 manufacturers feasibility report was not approved based upon the following votes:”
PFIZER INC shareholders rejected Shareholder proposal regarding independent board chairman policy at the 2023-04-27 meeting.
“The shareholder proposal regarding independent board chairman policy was not approved based upon the following votes:”
PFIZER INC shareholders rejected Shareholder proposal regarding ratification of termination pay at the 2023-04-27 meeting.
“The shareholder proposal regarding ratification of termination pay was not approved based upon the following votes:”
PFIZER INC shareholders approved Advisory vote on frequency of future advisory votes to approve executive compensation at the 2023-04-27 meeting.
“The proposal on the advisory vote on the frequency of future advisory votes to approve executive compensation received the following votes: For 1 year 3,766,703,452 For 2 years 14,391,226 For 3 years 89,089,799 Abstentions 15,686,294 Broker non-votes 822,779,764”
PFIZER INC shareholders approved Advisory approval of compensation of Named Executive Officers at the 2023-04-27 meeting.
“The proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers was approved based upon the following votes :”
PFIZER INC shareholders approved Ratification of selection of KPMG LLP as independent registered public accounting firm for 2023 at the 2023-04-27 meeting.
“The proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2023 fiscal year was approved based upon the following votes:”
PFIZER INC shareholders approved Election of Directors at the 2023-04-27 meeting.
“The nominees for election to the Company’s Board of Directors set forth in Item 1 to the Company’s Proxy Statement filed with the U.S. Securities and Exchange Commission on March 16, 2023 were elected to hold office until the Company’s next Annual Meeting of Shareholders, based upon the following votes:”
PFIZER INC entered into Agreement and Plan of Merger with Seagen Inc. valued at $229.00 per share (effective 2023-03-12).
“On March 12, 2023, Pfizer Inc. (“ Pfizer ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among Pfizer, Seagen Inc. (“ Seagen ”) and Aris Merger Sub, Inc., a wholly owned subsidiary of Pfizer (“ Merger Sub ”), pursuant to which, among other things, Merger Sub will be merged with and into Seagen (the “ Merger ”), with Seagen surviving the Merger as a wholly owned subsidiary of Pfizer.”
PFIZER INC reported Full-Year 2023 results: revenue $67.0 to $71.0 Billion, EPS $3.25 to $3.45. Guidance initiated.
“▪ Provides Full-Year 2023 Revenue Guidance (4) of $67.0 to $71.0 Billion and Adjusted Diluted EPS (3) Guidance of $3.25 to $3.45”
PFIZER INC reported Full-Year 2022 results: revenue $100.3 Billion, EPS $5.47.
“Full-Year 2022 Revenues of $100.3 Billion, An All-Time High for Pfizer, Reflecting 30% Operational Growth – Excluding Contributions from Paxlovid and Comirnaty (1) , Revenues Grew 2% Operationally ▪ Strong Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth – Excluding Contributions from Paxlovid and Comirnaty (1) , Revenues Grew 5% Operationally ▪ Full-Year 2022 Reported Diluted EPS (2) of $5.47, Up 42% Year-Over-Year, and Adjusted Diluted EPS (3) of $6.58, Up 62% Year-Over-Year, Both of Which Represent All-Time Highs for Pfizer”
PFIZER INC reported Fourth-Quarter 2022 results: revenue $24.3 Billion, EPS $0.87.
“Strong Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth – Excluding Contributions from Paxlovid and Comirnaty (1) , Revenues Grew 5% Operationally ▪ Full-Year 2022 Reported Diluted EPS (2) of $5.47, Up 42% Year-Over-Year, and Adjusted Diluted EPS (3) of $6.58, Up 62% Year-Over-Year, Both of Which Represent All-Time Highs for Pfizer ▪ Fourth-Quarter 2022 Reported Diluted EPS (2) of $0.87, Up 48% Year-Over-Year, and Adjusted Diluted EPS (3) of $1.14, Up 45% Year-Over-Year”
PFIZER INC: Amended and restated by-laws to incorporate universal proxy rule requirements for shareholder director nominations and other technical changes (effective 2022-12-09).
“On December 9, 2022, the Board of Directors of Pfizer Inc. (the ”Company“) amended and restated the Company’s by-laws (the ”By-laws“).”
PFIZER INC reported the third quarter of 2022 results: revenue $22,638, net income 8,608, EPS $1.51. Guidance raised.
“months of 2022 and 2021 (5) are summarized below. OVERALL RESULTS ($ in millions, except per share amounts) Third-Quarter Nine Months 2022 2021 Change 2022 2021 Change Revenues $ 22,638 $ 24,035 (6%) $ 76,040 $ 57,450 32% Reported Net Income (2) 8,608 8,146 6% 26,378 18,586 42% Reported Diluted EPS (2) 1.51 1.42 6% 4.60 3.27 41% Adjusted Income (3) 10,172 7,279”
Frank D'Amelio departed as Chief Financial Officer and Executive Vice President at PFIZER INC.
“As previously reported by the Company in a Current Report on Form 8-K filed with the Securities and Exchange Commission on November 19, 2021, the Company announced that Frank D’Amelio will be leaving his position as Chief Financial Officer and Executive Vice President after a nearly 15-year distinguished career with the Company and that Mr. D’Amelio would continue to serve as CFO until the appointment of a new chief financial officer, and will stay on as a special advisor until as late as December 31, 2022 in order to ensure a smooth transition of his CFO responsibilities.”
David M. Denton was elected as Chief Financial Officer, Executive Vice President at PFIZER INC.
“On April 11, 2022, Pfizer Inc. (the “Company”) announced that the Board of Directors of the Company elected David M. Denton as Chief Financial Officer, Executive Vice President of the Company and appointed Mr. Denton as a member of the Company's Executive Leadership Team, effective May 2, 2022 (the “Effective Date”).”
Michael McDermott was appointed as member of the Executive Leadership Team at PFIZER INC.
“The current leader of this function, Michael McDermott, will also become a member of the Executive Leadership Team.”
Frank D'Amelio departed as Chief Financial Officer and Executive Vice President of Global Supply at PFIZER INC.
“Frank D'Amelio will retire from his position as Chief Financial Officer and Executive Vice President of Global Supply”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.